



April 23, 2014

## **GlycoMimetics Appoints Seasoned Business Development Executive Armand Girard as New Vice President, Corporate Development**

GAITHERSBURG, Md.--(BUSINESS WIRE)-- [GlycoMimetics, Inc.](http://www.glycomimetics.com) (NASDAQ: GLYC) announced today that it has expanded its management team with the addition of Armand Girard as Vice President, Corporate Development. Mr. Girard has extensive partnering experience having completed collaborations, licenses, acquisitions and spinouts by and between leading pharmaceutical and biotech companies. As the GlycoMimetics Vice President of Corporate Development, he is responsible for corporate strategy, for pursuing partnering and licensing opportunities in support of the GlycoMimetics pipeline, and for managing the company's corporate and institutional alliances. Prior to joining GlycoMimetics, he held the position of Vice President for Technical Assessment at Shire Pharmaceuticals, and has more than 20 years of business development, research and development and project management experience. Prior to serving as Vice President for Technical Assessment, Mr. Girard served as a Senior Director for Business Development at Shire. He has held various roles in the biotechnology industry over the past 20 years for companies such as Strakan Life Sciences, Pro-Virus, Inc. and Otsuka Pharmaceuticals. Mr. Girard holds an M.B.A. from St. Joseph's University Haub School of Business, and a B.A. from Lehigh University.

"We are pleased to have Armand join the GlycoMimetics management team. He brings with him a great depth of experience in conducting business development transactions within the life science industry," said GlycoMimetics Chief Executive Officer [Rachel King](#). "His proven ability to support development pipelines through extensive partnering activities will be an asset to GlycoMimetics."

"It's very exciting to join GlycoMimetics at this time as the company has recently started trading on the NASDAQ and is poised for Pfizer's anticipated advancement of our lead candidate, rivipansel, into Phase 3 clinical study," said Mr. Girard. "I look forward to the opportunity to develop future partnerships and licensing deals - that will further drive progress towards making a difference in the lives of people living with sickle cell, cancer, and other serious diseases."

### **About GlycoMimetics, Inc.**

GlycoMimetics is a clinical stage biotechnology company focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. Glycomimetics are molecules that mimic the structure of carbohydrates involved in important biological processes. Using its expertise in carbohydrate chemistry and knowledge of carbohydrate biology, GlycoMimetics is developing a pipeline of glycomimetic drug candidates that inhibit disease-related functions of carbohydrates, such as the roles they play in inflammation, cancer and infection. For additional information, please visit the company's website.

This press release contains forward-looking statements regarding GlycoMimetics' planned activities with respect to the clinical development of rivipansel and other matters. Actual results may differ materially from those in these forward-looking statements. For a further description of the risks associated with these statements, as well as other risks facing GlycoMimetics, please see the risk factors described in the Company's annual report on form 10-K that was filed with the U.S. Securities and Exchange Commission on March 31, 2014, and other filings the company makes with the SEC from time to time. Forward-looking statements speak only as of the date of this release, and GlycoMimetics undertakes no obligation to update or revise these statements, except as may be required by law.

GlycoMimetics  
Brian Hahn, 240-243-1207  
[bhahn@glycomimetics.com](mailto:bhahn@glycomimetics.com)

Source: GlycoMimetics, Inc.

News Provided by Acquire Media